Chinese drug company Sinopharm and Parana state have agreed to launch the fourth major COVID-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said on Wednesday.
A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech.
Six coronavirus vaccines are now in phase III of human trials and one has been approved:— Denis Wirtz (@deniswirtz) July 28, 2020
AstraZeneca/U. Oxford (Sweden/UK)
as well as CanSino (approved, China)
(source: NYT) pic.twitter.com/yBolPXuUpp